Symbol="TCRT"
AssetType="Common Stock"
Name="Alaunos Therapeutics Inc"
Description="Alaunos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on discovering, acquiring, developing and commercializing a portfolio of immuno-oncology therapies to treat cancer patients. The company is headquartered in Houston, Texas."
CIK="1107421"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="ONE FIRST AVENUE, PARRIS BUILDING 34, NAVY YARD PLAZA, BOSTON, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="31546200"
EBITDA="-30559000"
PERatio="None"
PEGRatio="None"
BookValue="0.161"
DividendPerShare="0"
DividendYield="0"
EPS="-0.16"
RevenuePerShareTTM="0.013"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.312"
ReturnOnEquityTTM="-0.966"
RevenueTTM="2922000"
GrossProfitTTM="-19596000"
DilutedEPSTTM="-0.16"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="6.31"
AnalystTargetPrice="1.75"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="50.84"
PriceToBookRatio="5.02"
EVToRevenue="51.16"
EVToEBITDA="-4.306"
Beta="0.163"
num_52WeekHigh="4.01"
num_52WeekLow="0.12"
num_50DayMovingAverage="0.441"
num_200DayMovingAverage="0.609"
SharesOutstanding="240627000"
DividendDate="None"
ExDividendDate="None"
symbol="TCRT"
open="0.13"
high="0.13"
low="0.12"
price="0.12"
volume="2883104.00"
latest_trading_day="2023-08-18"
previous_close="0.13"
change="-0.01"
change_percent="-5.8734%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="78"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Trending High"
value_analysis="Bullish Trend"
Aroon_change="FALSE"
Aroon_momentum="22"
Volume_recent_avg="884630"
Change_recent_avg="-0.01"
Delta_recent_avg="0.04"
Variance_recent_avg="0.02"
Change_ratio_recent_avg="-1.78"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="22"
Aroon_momentum_negative="78"
image_negative_thumbnail_id_1="112"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0064.jpeg"
image_negative_thumbnail_id_2="514"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0091.jpeg"
image_neutral_thumbnail_id_1="521"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0078.jpeg"
image_neutral_thumbnail_id_2="530"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0069.jpeg"
image_positive_thumbnail_id_1="705"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0003.jpeg"
image_positive_thumbnail_id_2="994"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0156.jpeg"
image_professor_thumbnail_id_1="1178"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0012.jpeg"
image_professor_thumbnail_id_2="1177"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0011.jpeg"
